medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2007, Number 2

<< Back Next >>

Rev Biomed 2007; 18 (2)

Evidence of chromium effect in subjects with diabetes: a systematic review

Armendariz-Anguiano AL, Bacardí-Gascón M, Jiménez CA

Language: Spanish
References: 23
Page: 117-126
PDF size: 337.50 Kb.


ABSTRACT

Diabetes mellitus (DM) is one of the most important public health problems in both developed and developing countries. The treatment is comprehensive and includes several strategies. In addition to orthodox treatment, the use of alternative medicine has increased. In the U.S., 6% of the population with diabetes reported using chromium supplementation as an alternative therapy. However, the effect of chromium in reducing blood glucose and serum lipid levels is still controversial. The purpose of this review is to evaluate the available evidence of the effect of chromium supplementation for metabolic control of subjects with type 2 DM. We conducted a review of randomized, controlled, double-blind clinical trials registered on PubMed from January 1, 2004 to May 31, 2007 that included chromium supplement therapy in subjects with DM. We analyzed eight randomized clinical studies. Seven were parallel studies and one was a crossover study. Mean participation was 49 subjects (range: 29−68). In 4/8 studies, a statistically significant benefit was demonstrated on glucose levels, three on insulin levels, and one on glycosylated hemoglobin (HbA1c). In the reviewed studies, results suggest a slight short-term beneficial effect of chromium supplementation; however, results are not consistent.


REFERENCES

  1. Ahmann A. Guidelines and Performance measures for diabetes. The Am J Manag Care 2007; 13(2):S41-S46.

  2. Broadhurst CL, Domenico P. Clinical Studies on Chromium Picolinate supplementation in Diabetes Mellitus A Review. Diabetes Technol Ther 2006; 8(6): 677-87.

  3. Gutiérez-Vázquez I, Burguette - Cabañas Zacarías - Castillo R, Mata - Miranda P. Diabetes Mellitus Mortality, eleven years experience at a second level hospital. Salud Publica Mex 2006; 48(6):445.

  4. Blonde L. State of Diabetes Care in the United States. The Am J Manag Care 2007; 13(2):S36-S40.

  5. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med 2006; 30: 371-7.

  6. Jiménez-Cruz A, Bacardí-Gascón M. The Fattening burden of type 2 diabetes Mexicans: projections from early growth to adulthood. Diabetes Care 2004; 27(5): 1190-3.

  7. Ryan GJ, Wanko NS, Redman AR, Cook CB. Chromium as Adjunctive treatment for type 2 Diabetes. Ann Pharmacother 2003; 37:876-85.

  8. Expert Group on Vitamin s and Minerals: Review of chromium [Internet] 2002. Disponible en http://www.foodstandards.gov.uk/multimedia/pdfs/ reviewofchrome.pdf. Accesado el 1 de Junio de 2007.

  9. Cromo [Internet]. Disponible en http://ods.od.nih.gov/factsheets/chromium.asp. Accesado el 1 de Junio de 2007.

  10. Chromium and Diabetes Workshop Summary [Internet] Disponible en http://ods.od.nih.gov/news/conferences/ chromium_diabetes.html. Accesado el 1 de Junio de 2007.

  11. Cefalu WT, Hu FB. Role of chromium in human health and Diabetes. Diabetes Care 2004; 27(11):2741-51.

  12. Cromo [Internet]. Disponible en http://www.nlm.nih.gov/medlineplus/ency/article/003359.htm. Accesado el 1 de Junio de 2007.

  13. Cromo [Internet]. Disponible en http://www.nlm.nih.gov/medlineplus/ency/article/002418/htm. Accesado el 1 de Junio de 2007.

  14. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 2002; 76:148-55.

  15. Jain SK, Patel P, Rogier K, Jain S. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. Antioxid Redox Signal 2006; 8(1&2):238-41.

  16. Cheng HH, Lai MH, Hou WC, Huang CL. Antioxidants effects of chromium supplementation with type 2 Diabetes Mellitus and euglycemic subjects. J Agric Food Chem 2004;52:1385-9.

  17. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J 2005;149:632-6.

  18. Pei D, Hsieh CH, Hung YJ, Li JC, Lee CH, Kuo SW. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism 2006; 55:923-7.

  19. Kleefstra N, Houweling ST, Jansman FGA, Groenier KH, Gans ROB, Meyboom-De Jong B, Bakker SJL, Bilo HJG. Chromium treatment has No effect in patients with poorly controlled, insulin-treated type 2 diabetes in an Obese Western Population, a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006;29(3):521-5.

  20. Martin J, Wang ZQ, Zhang XH, Watchtel D, Volaufova J, Matthews DE, Cefalu WT. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006;29(8):1826-32.

  21. Singer GM, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 Diabetes Mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther 2006; 8(6):636-43.

  22. Racek J, Trefil L, Rajdl D, Mudrova V, Hunter D, Senft V. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 Diabetes Mellitus. Biol Trace Elem Res 2006; 109:215-30.

  23. Kleefstra N, Houweling ST, Bakker SJL, Verhoeven S, Gans ROB, Meyboom-De Jong B, Bilo HJG. Chromium treatment has No effect in patients with type 2 diabetes in an Western Population, a randomized, double-blind, placebo-controlled trial. Diabetes Care 2007;30(5):1092-6.




2020     |     www.medigraphic.com